Spread the love

A study from the Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany;  Dept. of Cardiology, University Hospital Giessen & Marburg, Giessen, Germany; Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Goethe University, Frankfurt, Germany; Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany; Hubrecht Institute, Utrecht, The Netherlands.

This study has reported that “Inhibition of miR-92a improves re-endothelialization and prevents neointima formation following vascular injury.

This study was published in the June 27, 2014 Circulation Research [I.F >10] by Prof. Daniel G. Sedding,  Jan-Marcus Daniel and others from the Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany

On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: Therapeutic insights into mechanisms that regulate vascular injury: MiRNA-100 ameliorates reendothelialization and suppresses neointima formation. MiRNA-100, by suppressing the expression of its target gene, it may prevent neointima formation. Together, this study suggests that pharmacological formulations encompassing “MiRNA-100 or its activators”  can be used to ameliorate reendothelialization and suppress neointima formation following vascular injury. 

Idea Proposed/Formulated by: Dr L Boominathan PhD

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Courtesy: When you cite drop us a line at info@genomediscovery.org

CitationBoominathan, Therapeutic insights into mechanisms that regulate vascular injury: MiRNA-100 ameliorates reendothelialization and suppresses neointima formation, 19/July/2014, 5.35 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org

*Research cooperation


Spread the love